Northern District Of California Dismisses Putative Class Action Against Biopharmaceutical Company With Prejudice

On March 3, 2026, Judge Richard Seeborg of the United States District Court for the Northern District of California granted a motion to dismiss a proposed class action complaint (the “Amended Complaint”) alleging that a biopharmaceutical company (the “Company”) and certain corporate officers violated Sections 11 and 15 of the Securities Act of 1933 (the “Securities Act”). In re BioAge Labs, Inc. Sec. Litig., No. 25-cv-00196 (N.D. Cal. Mar. 3, 2026).... By: A&O Shearman